MAP Pharmaceuticals, Inc. is a specialty pharmaceutical company developing innovative therapies and inhalation delivery platforms to treat a broad spectrum of respiratory and systemic diseases. MAP’s lead product is a proprietary formulation of budesonide for the treatment of pediatric asthma. The Company is also developing a series of respiratory and inhaled systemic drugs based on its Tempo™ Inhaler platform, including a rapid-relief treatment for migraine. Tempo™ is a next generation breath-actuated pMDI that automatically adjusts to different inhalation maneuvers but is exceptionally easy to use, enhancing compliance. Tempo™ also features a novel aerosol flow controller that ensures efficient and consistent delivery of the drug to the lungs, while minimizing oral deposition.